Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, child: Astrocytoma/Astrocytic tumors
Stage/Subtype:  recurrent childhood astrocytoma or other tumor of glial origin
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 25 for your search:
Start Over
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Selumetinib in Treating Young Patients with Recurrent or Refractory Low Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: PBTC-029B, NCI-2012-03173, CDR667932, PBTC-029, NCT01089101
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Everolimus in Treating Younger Patients With Neurofibromatosis Type 1 or Low Grade Gliomas That Did Not Responded to Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 09452, NCI-2010-01929, DOD W81XWH-05-1-0615, NCT01158651
Poly ICLC in Treating Younger Patients With Recurrent or Progressive Low Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: Poly-ICLC, NCI-2013-02084, NCT01188096
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients with Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 22
Trial IDs: ACNS1022, NCI-2012-00703, CDR0000728296, COG-ACNS1022, NCT01553149
Everolimus in Treating Younger Patients With Recurrent or Progressive Low-Grade Gliomas
Phase: Phase II
Type: Tissue collection/Repository, Treatment
Age: 3 to 21
Trial IDs: 120817, NCI-2012-02774, PNOC001, NCT01734512
Crizotinib and Dasatinib in Treating Younger Patients with Recurrent or Progressive Diffuse Intrinsic Pontine Glioma or High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 21
Trial IDs: SJHG12, NCI-2012-01240, NCT01644773
Oncolytic HSV-1716 in Treating Younger Patients with Refractory or Recurrent High Grade Glioma That Can Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 21
Trial IDs: PBTC-037, NCI-2013-00526, NCT02031965
Palbociclib Isethionate in Treating Younger Patients with Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: PBTC-042, NCI-2014-00640, NCT02255461
Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1414, NCI-2014-02410, NCT02323880
Pomalidomide in Treating Younger Patients with Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 20
Trial IDs: PBTC-043, NCI-2014-02182, CC-4047-PBTC-043, PPBTC-043_R04PAPP01, NCT02415153
Wild-Type Reovirus in Combination with Sargramostim in Treating Younger Patients with High-Grade Recurrent or Refractory Brain Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 10 to 21
Trial IDs: MC1472, NCI-2015-00665, MC1472 / Mayo IRB 14-006414, Mod14-006414-01, NCT02444546
Lenalidomide and Radiation Therapy in Treating Younger Patients with Pontine Glioma or High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: 10-C-0219, NCI-2011-02539, 100219, CDR0000687467, NCI-10-C-0219, NCT01226940, P10687, 8449, NCT01222754
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 21
Trial IDs: AFLACST1501, NCI-2015-02256, IRB00083793, NCT02644460
Conditioning Therapy Followed by Stem Cell Transplant in Treating Patients with High Risk or Relapsed Solid, Central Nervous System, or Germ Cell Tumors
Phase: No phase specified
Type: Treatment
Age: 70 and under
Trial IDs: 2011OC057, NCI-2013-02265, 1107M02641, MT2011-09C, NCT01505569
Cyclophosphamide or Thalidomide after Stem Cell Transplant in Treating Younger Patients with Solid Tumors
Phase: No phase specified
Type: Treatment
Age: 5 to 21
Trial IDs: 201209088, NCI-2012-01541, NCT01661400
Vemurafenib in Treating Younger Patients with Recurrent or Refractory BRAFV600E-Mutant Brain Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 25
Trial IDs: CC #120819, NCI-2014-00387, 076373, 092093, 120819 (PNOC 002), PNOC-002, NCT01748149
Fluorine F 18 Fluorodopa PET/MRI in Predicting Response in Younger Patients with Central Nervous System Tumors
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 21 and under
Trial IDs: 201303069, NCI-2013-00822, NCT01999270
MRI-Guided Laser Heat Ablation in Treating Younger Patients with Brain Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 3 to 21
Trial IDs: 201502062, NCI-2015-00403, NCT02372409
Start Over